Drug Trial Radar · NCT06015841
A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jul 24, 2023
Primary completion
Jun 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- AC Immune SAIndustry
- Sponsor type
- Industry
- Collaborators
- ICON Clinical Research
- First posted
- Aug 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson's disease.
Conditions
- Parkinson Disease
- Parkinson Disease 6, Early-Onset
Interventions
PlaceboBiological
The placebo is a solution matching the study treatment formulation.
ACI-7104.056 at Dose ABiological
The study treatment (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
ACI-7104.056 at Dose B (optional)Biological
The study treatment (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
ACI-7104.056 at Dose C (optional)Biological
The study treatment (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, or unlikely, possibly, probably or definitely related)Time frame: From Screening (ICF signature) to Week 100 in study part 1 and 2, and from Rescreening (ICF signature) to Week 78 in the extension phase
- Number of participants with abnormal MRI resultsTime frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase
- Number of participants with clinically significant changes in physical and neurological examination resultsTime frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase
- Number of participants reporting suicidal ideation or behavior using Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase
- Measurement of levels of specific antibodies against a-synuclein present in serum generated by ACI-7104.056Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Katholisches Klinikum Bochum GmbH
Bochum, Germany
Paracelsus-Kliniken Deutschland GmbH & Co. KGaA
Kassel, Germany
University Medical Centre Schleswig-Holstein
Kiel, Germany
Hospital De La Santa Creu I Sant Pau
Barcelona, Spain
Hospital Universitari Vall D Hebron
Barcelona, Spain
Policlinica Gipuzkoa
Donostia / San Sebastian, Spain
Hospital Universitario De La Princesa
Madrid, Spain
Hospital Universitario Puerta De Hierro De Majadahonda
Majadahonda, Spain
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Spain
King's College Hospital NHS Foundation Trust
London, United Kingdom
Re:Cognition Health Limited
London, United Kingdom
Northern Care Alliance NHS Foundation Trust
Salford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.